Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;19(9):562-572.
doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16.

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future

Hendrik Van Poppel  1 , Tit Albreht  2   3 , Partha Basu  4 , Renée Hogenhout  5 , Sarah Collen  6 , Monique Roobol  5
Affiliations
Review

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future

Hendrik Van Poppel et al. Nat Rev Urol. 2022 Sep.

Abstract

In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic prostate cancer and died of the disease; after the introduction of the serum PSA test, randomized controlled prostate cancer screening trials in the USA and Europe were conducted to assess the effect of PSA screening on prostate cancer mortality. Contradictory outcomes of the trials and the accompanying overdiagnosis resulted in recommendations against prostate cancer screening by organizations such as the United States Preventive Services Task Force. These recommendations were followed by a decline in PSA testing and a rise in late-stage diagnosis and prostate cancer mortality. Re-evaluation of the randomized trials, which accounted for contamination, showed that PSA-based screening does indeed reduce prostate cancer mortality; however, the debate about whether to screen or not to screen continues because of the considerable overdiagnosis that occurs using PSA-based screening. Meanwhile, awareness among the population of prostate cancer as a potentially lethal disease stimulates opportunistic screening practices that further increase overdiagnosis without the benefit of mortality reduction. However, in the past decade, new screening tools have been developed that make the classic PSA-only-based screening an outdated strategy. With improved use of PSA, in combination with age, prostate volume and with the application of prostate cancer risk calculators, a risk-adapted strategy enables improved stratification of men with prostate cancer and avoidance of unnecessary diagnostic procedures. This combination used with advanced detection techniques (such as MRI and _targeted biopsy), can reduce overdiagnosis. Moreover, new biomarkers are becoming available and will enable further improvements in risk stratification.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stang, A. & Jöckel, K. H. The impact of cancer screening on all-cause mortality: what is the best we can expect? Dtsch. Arztebl Int. 115, 481–486 (2018). - PubMed - PMC
    1. Loeb, S. et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 65, 1046–1055 (2014). - PubMed - PMC - DOI
    1. Aizer, A. A. et al. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J. Natl Compr. Cancer Netw. 13, 61–68 (2015). - DOI
    1. Wang, M. C. et al. Purification of a human prostate specific antigen. Investig. Urol. 17, 159–163 (1979).
    1. Papsidero, L. D. et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428–2432 (1980). - PubMed

Substances

  NODES
Association 3
INTERN 4
twitter 2